Interestingly, the FGFR1 amplification was identified by analysing a liquid biopsy with an NGS plasma test and then confirmed by fluorescent in situ hybridization (FISH), demonstrating the utility of noninvasive monitoring for tumour genotyping in a disease that is classically associated with availability of small histological tumour specimens. The gene discussed is FGFR1; the disease is neoplasm.